Your browser doesn't support javascript.
loading
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
Yue, M; Hinkle, K M; Davies, P; Trushina, E; Fiesel, F C; Christenson, T A; Schroeder, A S; Zhang, L; Bowles, E; Behrouz, B; Lincoln, S J; Beevers, J E; Milnerwood, A J; Kurti, A; McLean, P J; Fryer, J D; Springer, W; Dickson, D W; Farrer, M J; Melrose, H L.
Afiliação
  • Yue M; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA.
  • Hinkle KM; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA.
  • Davies P; MRC Phosphorylation Unit, University of Dundee, DD1 4HN, Scotland, UK.
  • Trushina E; Dept. of Neurology, Dept. of Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, Rochester, MN 55905, USA.
  • Fiesel FC; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA.
  • Christenson TA; Mayo Clinic Electron Microscopy Core Facility, Rochester, MN 55905, USA.
  • Schroeder AS; Dept. of Neurology, Dept. of Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, Rochester, MN 55905, USA.
  • Zhang L; Dept. of Neurology, Dept. of Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, Rochester, MN 55905, USA.
  • Bowles E; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA.
  • Behrouz B; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA.
  • Lincoln SJ; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA.
  • Beevers JE; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA.
  • Milnerwood AJ; Center for Applied Neurogenetics, University of British Columbia, V6T 2B5, Canada.
  • Kurti A; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA.
  • McLean PJ; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA; Neurobiology of Disease Graduate Program, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.
  • Fryer JD; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA; Neurobiology of Disease Graduate Program, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.
  • Springer W; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA; Neurobiology of Disease Graduate Program, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.
  • Dickson DW; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA; Neurobiology of Disease Graduate Program, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.
  • Farrer MJ; Center for Applied Neurogenetics, University of British Columbia, V6T 2B5, Canada.
  • Melrose HL; Dept. of Neuroscience, Mayo Clinic Jacksonville, Jacksonville FL 32224, USA; Neurobiology of Disease Graduate Program, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA. Electronic address: melrose.heather@mayo.edu.
Neurobiol Dis ; 78: 172-95, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25836420
ABSTRACT
Mutations in the LRRK2 gene represent the most common genetic cause of late onset Parkinson's disease. The physiological and pathological roles of LRRK2 are yet to be fully determined but evidence points towards LRRK2 mutations causing a gain in kinase function, impacting on neuronal maintenance, vesicular dynamics and neurotransmitter release. To explore the role of physiological levels of mutant LRRK2, we created knock-in (KI) mice harboring the most common LRRK2 mutation G2019S in their own genome. We have performed comprehensive dopaminergic, behavioral and neuropathological analyses in this model up to 24months of age. We find elevated kinase activity in the brain of both heterozygous and homozygous mice. Although normal at 6months, by 12months of age, basal and pharmacologically induced extracellular release of dopamine is impaired in both heterozygous and homozygous mice, corroborating previous findings in transgenic models over-expressing mutant LRRK2. Via in vivo microdialysis measurement of basal and drug-evoked extracellular release of dopamine and its metabolites, our findings indicate that exocytotic release from the vesicular pool is impaired. Furthermore, profound mitochondrial abnormalities are evident in the striatum of older homozygous G2019S KI mice, which are consistent with mitochondrial fission arrest. We anticipate that this G2019S mouse line will be a useful pre-clinical model for further evaluation of early mechanistic events in LRRK2 pathogenesis and for second-hit approaches to model disease progression.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Dopamina / Proteínas Serina-Treonina Quinases / Mitocôndrias Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Dopamina / Proteínas Serina-Treonina Quinases / Mitocôndrias Idioma: En Ano de publicação: 2015 Tipo de documento: Article